Astellas Enters into Definitive Agreement to Acquire Iveric Bio

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Iveric bio, Inc. (NASDAQ: ISEE, CEO: Glenn P. Sblendorio,...

Related Keywords

United States ,Japan ,Tokyo ,Glennp Sblendorio ,Pravinu Dugel ,Iveric Bio ,Avacincaptad Pegol ,Naoki Okamura ,Wilmer Cutler Pickering Hale ,Astellas Us Holding Inc ,Blackrock Inc ,Centerview Partners ,Nasdaq ,Exchange Commission ,Bofa Securities Inc ,Astellas Pharma Inc ,Drug Administration ,Vanguard Group Inc ,Jones Day ,Jpmorgan Securities Japan Co Ltd ,A Related Party ,Jp Morgan Securities ,Meagher Flom ,Companies To Create World ,Prnewswire Astellas Pharma Inc ,Berry Merger Sub Inc ,Create World Class Ophthalmology ,Lead Program ,Potential Treatment ,Geographic Atrophy ,Astella Primary Focus ,Berry Merger Sub ,Age Related Macular Degeneration ,Chief Executive Officer ,Focus Area Approach ,Primary Focuses ,New Drug Application ,Prescription Drug User Fee Act ,Corporate Strategic Plan ,Primary Focus ,Way Parsippany ,Track Capital ,Annual Report ,Iveric Bio Shares Outstanding ,Bofa Securities ,Primary Focu ,Securities Litigation Reform Act ,Principal Risk ,Iveric Bio Annual Reports ,Quarterly Reports ,United States Securities ,